Halozyme Therapeutics (HALO) Income towards Parent Company (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Income towards Parent Company data on file, last reported at $150.0 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at $150.0 million, up 27.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $348.9 million (down 28.13% YoY), and the FY2025 annual result was $316.9 million, down 28.64% from the prior year.
• Income towards Parent Company climbed to $150.0 million in Q1 2026 per HALO's latest filing, from -$141.6 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $175.3 million in Q3 2025 and troughed at -$141.6 million in Q4 2025.
• A 5-year average of $82.0 million and a median of $81.8 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company surged 229.53% in 2023, then plunged 203.34% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at $57.7 million in 2022, then surged by 47.98% to $85.4 million in 2023, then surged by 60.46% to $137.0 million in 2024, then sank by 203.34% to -$141.6 million in 2025, then jumped by 205.97% to $150.0 million in 2026.
• Business Quant data shows HALO's Income towards Parent Company at $150.0 million in Q1 2026, -$141.6 million in Q4 2025, and $175.3 million in Q3 2025.